LFCR News & Events

Lifecore announced it has signed a new agreement with a global pharmaceutical company. Under the terms of the agreement, Lifecore will perform technical transfer services to support the commercial production of an injectable suspension product for neurological disorders.

Lifecore announced that it has signed a manufacturing services agreement with a provider of ophthalmic disease management solutions. Under the terms of the agreement, Lifecore will perform process development and technical transfer services in support of anticipated commercial manufacturing upon regulatory approval. "We are pleased to announce another customer win and the opportunity to support an important new technical transfer program," said Paul Josephs, chief executive officer of Lifecore. "This agreement reflects Lifecore's recognized, technical expertise and specialized manufacturing capabilities in the ophthalmic injectables space."

Reports Q1 revenue $23.19M, consensus $25.96M. "During the first quarter, Lifecore continued to successfully execute the three pillars of its growth strategy - maximizing our existing commercial business, advancing our development pipeline toward commercialization, and adding high-quality, new programs to our pipeline through business development. We believe our continued execution across these pillars positions Lifecore for sustained growth, including our goal of achieving a 12% revenue CAGR and EBITDA margins above 25% by the end of 2029. In the near-term, we remain confident in our full-year expectations and reaffirm our 2026 guidance."